From the Journals

Melanoma incidence increased in older non-Hispanic whites


 

FROM JAMA DERMATOLOGY

The incidence of melanoma has increased in non-Hispanic whites in recent years, particularly in men over 54 years of age and women over 44 years of age, reported Dawn M. Holman, MPH, of the division of cancer prevention and control at the Centers for Disease Control and Prevention, and her coauthors.

In non-Hispanic white females aged 15 years and older, 131,976 melanomas were diagnosed between January 2010 and December 2014. In non-Hispanic white males, 192,979 melanomas were diagnosed during this time period. More than 70% of melanomas were diagnosed in patients aged 55 years or older, the authors reported. In females, melanoma incidence rates ranged from 4.5/100,000 population in those aged 15-24 years to 60.9/100,000 population in those aged 85 years and older. For males, melanoma incidence ranged from 2.0/100,000 population in those aged 15-24 years to 198.3/100,000 population in men aged 85 years and older.

Huntstock/Thinkstock

Investigators analyzed data from the CDC National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program. Melanoma incidence rates and average annual counts by 10-year age groups were calculated from January 2010 to December 2014, as was average annual percent change (AAPC) by 10-year age groups from January 2005 to December 2014.

Overall, the increase in melanoma incidence was statistically significant for both males and females 15 years of age and older (AAPC, 1.4; P less than .05). However, melanoma incidence decreased significantly in younger patients aged 15-24 years, 25-34 years, and 35-44 years (AAPC, –5.1, –1.7, and –0.5 respectively; P less than .05), and increased significantly in those aged 55-64 years, 65-74 years, 75-84 years, and older than 85 years (AAPC, 1.3, 2.5, 3.6, and 4.6 respectively; P less than .05). The increase in melanoma incidence was statistically significant in men older than 54 years and in women older than 44 years, Ms. Holman and her associates reported in a research letter in JAMA Dermatology.

Pages

Recommended Reading

First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
MDedge Dermatology
FDA expands approval of nivolumab for melanoma treatment
MDedge Dermatology
Perceptions of Tanning Risk Among Melanoma Patients With a History of Indoor Tanning
MDedge Dermatology
Nonmalignant Cutaneous Findings Associated With Vemurafenib
MDedge Dermatology
Desmoplastic melanoma yields to checkpoint inhibitors
MDedge Dermatology
Sentinel node biopsy: Who needs it?
MDedge Dermatology
Supportive oncodermatology: Cancer advances spawn new subspecialty
MDedge Dermatology
Neoadjuvant dabrafenib and trametinib improves event-free survival in resectable melanoma
MDedge Dermatology
Mobile Medical Apps for Patient Education: A Graded Review of Available Dermatology Apps
MDedge Dermatology
Be alert for BAP1 mutations in hereditary melanomas
MDedge Dermatology